Mga Batayang Estadistika
| LEI | 5493003Z6741WNLG7H43 |
| CIK | 1770787 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 10x Genomics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 8, 2025 |
6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 925 401 7300 Exhibit 10.1 MUTUAL ARBITRATION AGREEMENT This Mutual Arbitration Agreement (“Agreement”) is between the employee (“Employee”) and 10x Genomics, Inc. and its subsidiaries and affiliates (“10x” or the “Company”) (collectively, the “Parties”). The Federal Arbitration Act (9 U.S.C. § 1 et seq.) (“FAA”) applies to and governs this Agreem |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 7, 2025 |
10x Genomics Reports Second Quarter 2025 Financial Results Exhibit 99.1 10x Genomics Reports Second Quarter 2025 Financial Results PLEASANTON, Calif. August 7, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates •Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, re |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 8, 2025 |
10x Genomics Reports First Quarter 2025 Financial Results Exhibit 99.1 10x Genomics Reports First Quarter 2025 Financial Results PLEASANTON, Calif. May 8, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates •Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| February 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) 10x Genomics, Inc. |
|
| February 13, 2025 |
Form of At-Will Employment, Confidential Information and Invention Assignment Agreement 6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 925 401 7300 Exhibit 10.8 AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, AND INVENTION ASSIGNMENT AGREEMENT This At-Will Employment, Confidential Information, and Invention Assignment Agreement (the “Agreement”) is entered into between the undersigned employee (“Employee”) and 10x Genomics, Inc., for the benefit of 10x Genomics, Inc., and any of i |
|
| February 13, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025. As filed with the Securities and Exchange Commission on February 13, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 45-5614458 (I.R.S. E |
|
| February 13, 2025 |
6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 925 401 7300 Exhibit 10.17 MUTUAL ARBITRATION AGREEMENT This Mutual Arbitration Agreement (“Agreement”) is between the employee (“Employee”) and 10x Genomics, Inc. and its subsidiaries and affiliates (“10x” or the “Company”) (collectively, the “Parties”). The Federal Arbitration Act (9 U.S.C. § 1 et seq.) (“FAA”) applies to and governs this Agree |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| February 12, 2025 |
Exhibit 99.1 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025 PLEASANTON, Calif. February 12, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates •Revenue was $165.0 millio |
|
| February 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 13, 2025 |
Exhibit 99.1 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially PLEASANTON, Calif., January 12, 2025 — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter a |
|
| November 8, 2024 |
TXG / 10x Genomics, Inc. / Nikko Asset Management Americas, Inc. - SC 13G Passive Investment SC 13G 1 ef20038329sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* 10x GENOMICS, INC. (Name of Issuer) Class A common stock, par value $0.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement |
|
| November 5, 2024 |
TXG / 10x Genomics, Inc. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment SC 13G 1 txg1028240sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* 10x Genomics, Inc. (Name of Issuer) Class A common stock, par value $0.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check |
|
| October 29, 2024 |
Form of 2019 Omnibus Incentive Plan Stock Option Award Notice and Agreement. Exhibit 10.1.1 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD NOTICE Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Stock Option Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have the meanings set forth in the Sto |
|
| October 29, 2024 |
Employment Offer Letter by and between the Registrant and Adam Taich dated August 7, 2024 6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 925 401 7300 Exhibit 10.3 August 6, 2024 Adam Taich Dear Adam, I am pleased to offer you a position with 10x Genomics, Inc. (the “Company” or “10x”) as Chief Financial Officer. Your start date is expected to be August 12, 2024, or such other date as may be mutually agreed upon between you and the Company (“Start Date”). If you decide to join us, |
|
| October 29, 2024 |
Form of 2019 Omnibus Incentive Plan Restricted Stock Unit Award Notice and Agreement. Exhibit 10.1.2 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD NOTICE Participant has been granted Restricted Stock Units with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have th |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 29, 2024 |
10x Genomics Reports Third Quarter 2024 Financial Results Exhibit 99.1 10x Genomics Reports Third Quarter 2024 Financial Results PLEASANTON, Calif. October 29, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights •Revenue was $151.7 million for the third quarter, in line with the company’s preliminary announcement, a 1% decr |
|
| October 29, 2024 |
Form of 2019 Employee Stock Purchase Plan Subscription Agreement. Exhibit 10.2.1 10X GENOMICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN SUBSCRIPTION AGREEMENT (U.S. and Non-U.S. Participants) Capitalized terms used but not otherwise defined herein shall have the respective meanings given to such terms in the 10x Genomics, Inc. (the “Company”) 2019 Employee Stock Purchase Plan (the “Plan”). 1.By electronically accepting this 2019 Employee Stock Purchase Plan Subscr |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 9, 2024 |
10x Genomics Announces Preliminary Select Third Quarter 2024 Results Exhibit 99.1 10x Genomics Announces Preliminary Select Third Quarter 2024 Results PLEASANTON, Calif., October 9, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024. Preliminary Select Third Quarter 2024 Results •Revenue of approximately $151.7 million for the third quarter e |
|
| October 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 12, 2024 |
TXG / 10x Genomics, Inc. / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 8, 2024 |
10x Genomics Reports Second Quarter 2024 Financial Results Exhibit 99.1 10x Genomics Reports Second Quarter 2024 Financial Results PLEASANTON, Calif. August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights •Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily dri |
|
| August 8, 2024 |
10x Genomics Announces Senior Leadership Changes Exhibit 99.2 10x Genomics Announces Senior Leadership Changes PLEASANTON, Calif., August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. •Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution |
|
| August 8, 2024 |
Amended and Restated Non-Employee Director Compensation Policy 6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 925 401 7300 10xgenomics.com Exhibit 10.1 10x Genomics, Inc. Non-Employee Director Compensation Policy (Amended and Restated Effective as of April 26, 2024) Purpose The purpose of this Non-Employee Director Compensation Policy (this “Policy”) is to establish the cash and equity compensation for non-employee members of the Board of Directors (the |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 13, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 30, 2024 |
10x Genomics Reports First Quarter 2024 Financial Results Exhibit 99.1 10x Genomics Reports First Quarter 2024 Financial Results PLEASANTON, Calif. April 30, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights •Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spati |
|
| April 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| February 15, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 10X GENOMICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 10x Genomics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.PERSONS SUBJECT TO POLICY This P |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| February 15, 2024 |
Form of 2019 Employee Stock Purchase Plan Subscription Agreement. Exhibit 10.6.1 10X GENOMICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN SUBSCRIPTION AGREEMENT (U.S. and Non-U.S. Participants) Capitalized terms used but not otherwise defined herein shall have the respective meanings given to such terms in the 10x Genomics, Inc. (the “Company”) 2019 Employee Stock Purchase Plan (the “Plan”). 1.By electronically accepting this 2019 Employee Stock Purchase Plan Subscr |
|
| February 15, 2024 |
As filed with the Securities and Exchange Commission on February 15, 2024. As filed with the Securities and Exchange Commission on February 15, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 45-5614458 (I.R.S. E |
|
| February 15, 2024 |
Exhibit 10.28 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the “Agreement”) by and between James Wilbur (“Executive”) and 10x Genomics, Inc., a Delaware corporation (the “Company”), is made effective as of the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executive’s services to the Company and its affiliates w |
|
| February 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) 10x Genomics, Inc. |
|
| February 15, 2024 |
Form of 2019 Omnibus Incentive Plan Stock Option Award Notice and Agreement. Exhibit 10.5.1 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD NOTICE Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Stock Option Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have the meanings set forth in the Sto |
|
| February 15, 2024 |
Amended and Restated Insider Trading Exhibit 19.1 10X GENOMICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY (Amended and Restated on October 24, 2023) INTRODUCTION 10x Genomics, Inc. (together with its subsidiaries, the “Company”) opposes the unauthorized disclosure of any nonpublic information acquired in the course of your service with the Company and the misuse of material nonpublic information in securities trading. Any such |
|
| February 15, 2024 |
Exhibit 99.1 10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024 Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif. February 15, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and ful |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 15, 2024 |
Form of 2019 Omnibus Incentive Plan Restricted Stock Unit Award Notice and Agreement. Exhibit 10.5.2 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD NOTICE Participant has been granted Restricted Stock Units with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have th |
|
| February 13, 2024 |
TXG / 10x Genomics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0149-10xgenomicsincclassa.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: 10x Genomics Inc Class A Title of Class of Securities: Common Stock CUSIP Number: 88025U109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 8, 2024 |
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results Exhibit 99.1 10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results PLEASANTON, Calif., January 8, 2024 — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023. Preliminary, Unaudited Select Fourth Quarter 2023 Financial Results •Revenue |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 2, 2023 |
10x Genomics Reports Third Quarter 2023 Financial Results Exhibit 99.1 10x Genomics Reports Third Quarter 2023 Financial Results PLEASANTON, Calif. November 2, 2023 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights •Revenue was $153.6 million for the third quarter, a 17% increase over the corresponding period of 2022, driven b |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 4, 2023 |
Amended and Restated Non-Employee Director Compensation Policy 10xgenomics.com Exhibit 10.1 10x Genomics, Inc. Non-Employee Director Compensation Policy (Amended and Restated Effective as of April 28, 2023) Purpose The purpose of this Non-Employee Director Compensation Policy (this “Policy”) is to establish the cash and equity compensation for non-employee members of the Board of Directors (the “Board”) of 10x Genomics, Inc. (the “Company”) in a manner that a |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2023 |
10x Genomics Reports Second Quarter 2023 Financial Results Exhibit 99.1 10x Genomics Reports Second Quarter 2023 Financial Results PLEASANTON, Calif. August 3, 2023 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights •Revenue was $146.8 million for the second quarter, representing a 28% increase over the corresponding period of 2022. |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 17, 2023 |
Exhibit 99.1 10x Genomics Wins Permanent Injunction Against NanoString’s CosMx Products 10x Genomics is seeking additional injunctions to protect its intellectual property PLEASANTON, Calif. May 17, 2023 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation against NanoString Technologies, Inc. (Nasda |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 3, 2023 |
10x Genomics Reports First Quarter 2023 Financial Results Exhibit 99.1 10x Genomics Reports First Quarter 2023 Financial Results PLEASANTON, Calif. May 3, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights •Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. •Surpassed 5,000 customer publications using 10x G |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| February 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) 10x Genomics, Inc. |
|
| February 16, 2023 |
As filed with the Securities and Exchange Commission on February 16, 2023. As filed with the Securities and Exchange Commission on February 16, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 45-5614458 (I.R.S. E |
|
| February 16, 2023 |
Form of 2019 Employee Stock Purchase Plan Notice of Contribution Percentage Change or Withdrawal. Exhibit 10.6.2 10x GENOMICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN NOTICE OF CONTRIBUTION PERCENTAGE CHANGE OR WITHDRAWAL (THE “NOTICE”) Capitalized terms used but not otherwise defined herein shall have the respective meanings given to such terms in the 10x Genomics, Inc. (the “Company”) 2019 Employee Stock Purchase Plan (the “Plan”). ☐ I hereby elect to electronically change the contribution pe |
|
| February 16, 2023 |
2019 Employee Stock Purchase Plan Subscription Agreement. Exhibit 10.6.1 10x GENOMICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN SUBSCRIPTION AGREEMENT Capitalized terms used but not otherwise defined herein shall have the respective meanings given to such terms in the 10x Genomics, Inc. (the “Company”) 2019 Employee Stock Purchase Plan (the “Plan”). 1.By electronically accepting this 2019 Employee Stock Purchase Plan Subscription Agreement (this “Subscript |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| February 15, 2023 |
Exhibit 99.1 10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023 Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021 PLEASANTON, Calif. February 15, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outl |
|
| February 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 14, 2023 |
TXG / 10x Genomics, Inc. Class A / Venrock Associates VI, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236584d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 9, 2023 |
TXG / 10x Genomics, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0133-10xgenomicsincclassa.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: 10X Genomics Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 88025U109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box t |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 3, 2022 |
2019 Omnibus Incentive Plan Stock Option Award Notice and Agreement. Exhibit 10.1 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD NOTICE Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Stock Option Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have the meanings set forth in the Stock |
|
| November 3, 2022 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF 10X GENOMICS, INC. (Effective October 28, 2022) ARTICLE I Offices SECTION 1.01 Registered Office. The registered office and registered agent of 10x Genomics, Inc. (the ?Corporation?) shall be as set forth in the Restated Certificate of Incorporation (as defined below). The Corporation may also have offices in such other places in the United States or else |
|
| November 3, 2022 |
019 Omnibus Incentive Plan Restricted Stock Unit Award Notice and Agreement. Exhibit 10.2 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD NOTICE Participant has been granted Restricted Stock Units with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have the |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 2, 2022 |
10x Genomics Reports Third Quarter 2022 Financial Results Exhibit 99.1 10x Genomics Reports Third Quarter 2022 Financial Results PLEASANTON, Calif. November 2, 2022 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights ?Revenue was $131.1 million for the third quarter, representing a 5% increase over the corresponding period of 2021 and a 14% increase over second quarter of 2 |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 9, 2022 |
Employment Offer Letter by and between the Registrant and James Wilbur dated July 12, 2022. Exhibit 10.1 July 6, 2022 James Wilbur Dear Jim, I am pleased to offer you a position with 10x Genomics, Inc. (the ?Company? or ?10x?) as Chief Commercial Officer. Your start date is expected to be July 27, 2022, or such other date as may be mutually agreed upon between you and the Company (?Start Date?). Your position will be based remotely in Maryland until your move to California, expected in s |
|
| August 8, 2022 |
10x Genomics Reports Second Quarter 2022 Financial Results Exhibit 99.1 10x Genomics Reports Second Quarter 2022 Financial Results PLEASANTON, Calif. August 8, 2022 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights ?Revenue was $114.6 million for the second quarter, representing a 1% decrease over the corresponding period of 2021. ?Announced the breakthrough capability of sing |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| July 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 14, 2022 |
10x Genomics Names Jim Wilbur as Chief Commercial Officer Exhibit 99.2 10x Genomics Names Jim Wilbur as Chief Commercial Officer PLEASANTON, Calif., July 14, 2022 ? Following a comprehensive search process, 10x Genomics, Inc. (Nasdaq: TXG), today announced the hiring of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27. In this role, Wilbur will be responsible for driving commercial strategy and execution and leading the company?s sales, |
|
| July 14, 2022 |
10x Genomics Announces Preliminary Second Quarter 2022 Revenue Exhibit 99.1 10x Genomics Announces Preliminary Second Quarter 2022 Revenue PLEASANTON, Calif., July 14, 2022 ? 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022. This represents an approximate 1% decreas |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2022 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 10x Genomics, Inc. Non-Employee Director Compensation Policy (Amended and Restated Effective as of April 29, 2022) Purpose The purpose of this Non-Employee Director Compensation Policy (this “Policy”) is to establish the cash and equity compensation for non-employee members of the Board of Directors (the “Board”) of 10x Genomics, Inc. (the “Company”) in a manner that aligns their inte |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 4, 2022 |
Exhibit 99.1 10x Genomics Reports First Quarter 2022 Financial Results Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif. May 4, 2022 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2022. Recent Highlights ?Revenue was $114.5 million for the first quarter, representing an 8% increase over the corresponding period of 2021. ?Show |
|
| April 29, 2022 |
DEFA14A 1 txg-2022defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2022 |
DEF 14A 1 txg-2022def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 18, 2022 |
Separation Agreement between Bradford J. Crutchfield TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the ?Agreement?) by and between Bradford J. |
|
| February 18, 2022 |
Description of the Registrant’s Securities. Exhibit 4.2 DESCRIPTION OF SECURITIES CAPITAL STOCK 10x Genomics, Inc. (?10x,? "we," "us" or ?our?) has one class of securities, our Class A common stock, par value $0.00001 per share (?Class A Common Stock?), registered under Section 12 of the Securities Exchange Act of 1934, as amended. Shares of our Class A Common Stock are traded on The Nasdaq Stock Market LLC under the trading symbol ?TXG.? T |
|
| February 18, 2022 |
As filed with the Securities and Exchange Commission on February 18, 2022. S-8 1 txg-s82022.htm S-8 As filed with the Securities and Exchange Commission on February 18, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizat |
|
| February 18, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) 10x Genomics, Inc. |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| February 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2022 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 16, 2022 |
Exhibit 99.1 10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022 FY 2021 revenue growth of 64% and Q4 2021 revenue growth of 28% over the corresponding periods of 2020 PLEASANTON, Calif. February 16, 2022 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided ou |
|
| February 14, 2022 |
TXG / 10x Genomics, Inc. Class A / Venrock Associates VI, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm226174d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 9, 2022 |
TXG / 10x Genomics, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: 10X Genomics Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 88025U109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 3, 2021 |
Exhibit 99.1 10x Genomics Reports Third Quarter 2021 Financial Results Q3 2021 revenue growth of 74% over prior year and 8% over prior quarter PLEASANTON, Calif. November 3, 2021 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2021. Recent Highlights ?Revenue was $125.3 million for the third quarter, representing a 74% increase over the |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2021 |
Exhibit 99.1 10x Genomics Reports Second Quarter 2021 Financial Results Q2 2021 revenue growth of 170% over prior year and 9% over prior quarter PLEASANTON, Calif. August 4, 2021 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights ?Revenue was $115.8 million for the second quarter, representing a 170% increase over the c |
|
| July 30, 2021 |
TXG / 10x Genomics, Inc. Class A / Saxonov Serge - SC 13D/A Activist Investment SC 13D/A 1 d580374dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) Serge Saxonov Chief Executive Officer 10x Genomics, Inc. 6230 Stoneridge |
|
| July 30, 2021 |
TXG / 10x Genomics, Inc. Class A / Hindson Benjamin J. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) Benjamin J. Hindson Chief Scientific Officer and President 10x Genomics, Inc. 6230 Stoneridge Mall Road Pleasant |
|
| July 27, 2021 |
SETTLEMENT AND PATENT CROSS LICENSE AGREEMENT Page 1 Exhibit 10.1 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. SETTLEMENT AND PATENT CROSS LICENSE AGREEMENT This SETTLEMENT AND PATENT CROSS LICENSE AGREEMENT (?Agreement?) is entered into as of July 26, 2021 (the ?Effective Date?) by and between |
|
| July 27, 2021 |
Exhibit 99.1 10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes PLEASANTON, Calif., July 27, 2021 - 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolve |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 15, 2021 |
Exhibit 10.1 Third Amendment This Third Amendment (this ?Amendment?) is dated as of June 10, 2021 (the ?Effective Date?) and entered into by and between 6200 Stoneridge Mall Road Investors LLC, a Delaware limited liability company (?Landlord?) and 10X Genomics, Inc., a Delaware corporation (?Tenant?). Recitals A.Landlord and Tenant are parties to that certain Lease Agreement dated August 2, 2018 ( |
|
| June 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 2, 2021 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 10x Genomics, Inc. Non-Employee Director Compensation Policy (Amended and Restated Effective as of May 30, 2021) Purpose The purpose of this Non-Employee Director Compensation Policy (this ?Policy?) is to establish the cash and equity compensation for non-employee members of the Board of Directors (the ?Board?) of 10x Genomics, Inc. (the ?Company?) in a manner that aligns their intere |
|
| May 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2021 |
Exhibit 99.1 10x Genomics Reports First Quarter 2021 Financial Results Q1 2021 revenue growth of 47% over prior year PLEASANTON, Calif. May 5, 2021 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2021. Recent Highlights ?Revenue was $105.8 million for the first quarter, representing a 47% increase over the corresponding period of 2020 ?Laun |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 23, 2021 |
Employment Offer Letter by and between the Registrant and Ruth De Backer. Exhibit 10.9 Ruth De Backer New York, NY Dear Ruth, I am pleased to offer you a position with 10x Genomics, Inc. (the ?Company? or ?10x?) as Chief Business Officer. Your position will be based remotely in New York, New York until your move to California, expected in summer 2020, after which you will be based in Pleasanton, California. The following will outline the terms of your employment: Positi |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on February 26, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 45-5614458 (I.R.S. E |
|
| February 26, 2021 |
Execution Version US-DOCS\117747603 233678486 v12 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION BY AND AMONG 10X GENOMICS, INC. |
|
| February 26, 2021 |
EXHIBIT 10.7 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD NOTICE Participant has been granted Restricted Stock Units with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Notice will have the |
|
| February 26, 2021 |
003606-0002-17195-31424414.11 EXHIBIT 10.10 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD NOTICE Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Nonqualified Stock Option Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this A |
|
| February 26, 2021 |
003606-0002-17195-31515784.5 EXHIBIT 10.11 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD NOTICE Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Nonqualified Stock Option Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Aw |
|
| February 26, 2021 |
003606-0002-17195-Active.31836599.5 EXHIBIT 10.9 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD NOTICE (NON-EMPLOYEE DIRECTOR) Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Nonqualified Stock Option Agreement to which this Award Notice is attached. Capitalized terms u |
|
| February 26, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| February 26, 2021 |
003606-0002-17195-31452384.7 EXHIBIT 10.8 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD NOTICE Participant has been granted an Option with the terms set forth in this Award Notice, and subject to the terms and conditions of the Plan and the Incentive Stock Option Agreement to which this Award Notice is attached. Capitalized terms used and not defined in this Award Not |
|
| February 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 17, 2021 |
EX-99.1 2 txg-fy2020earningsreleasee.htm EX-99.1 Exhibit 99.1 10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021 Q4 2020 revenue growth of 49% over prior year PLEASANTON, Calif. February 17, 2021 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook fo |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2020 (Date |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) * 10X Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2020 (Date of Event Which |
|
| February 16, 2021 |
SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value (Title of Cla |
|
| February 12, 2021 |
Joint Filing Agreement Pursuant to Rule 13d-1 EX-99.1 EXHIBIT 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rule |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: 10X Genomics Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 88025U109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| November 12, 2020 |
ex104 LEASE AGREEMENT BY AND BETWEEN 6200 STONERIDGE MALL ROAD INVESTORS LLC, a Delaware limited liability company AS LANDLORD and 10X GENOMICS, INC. |
|
| November 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 12, 2020 |
EXHIBIT 10.3 AMENDMENT TO AGREEMENT FOR PURCHASE AND SALE THIS AMENDMENT TO AGREEMENT FOR PURCHASE AND SALE is made and entered into as of October 15, 2020, by and between EQUITY ONE (WEST COAST PORTFOLIO) LLC, a Florida limited liability company (“Seller”), and 10x GENOMICS, a Delaware corporation (“Buyer”). RECITALS A. Buyer and Seller are the parties to that certain Agreement for Purchase and S |
|
| November 10, 2020 |
10x Genomics Reports Third Quarter 2020 Financial Results Exhibit 99.1 10x Genomics Reports Third Quarter 2020 Financial Results PLEASANTON, Calif. November 10, 2020 ? 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights ?Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 16, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on October 16, 2020 Registration No. |
|
| October 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| October 5, 2020 |
Exhibit 99.1 10x Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB PLEASANTON, Calif. October 5, 2020 – Continuing on its mission of mastering biology to advance human health, 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., deve |
|
| September 11, 2020 |
The following is a chronology of key events since our inception. 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-248654 Registration No. 333-248727 Prospectus 4,000,000 shares Class A common stock We are offering 4,000,000 shares of our Class A common stock to be sold in this offering. We have two classes of common stock, Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B co |
|
| September 10, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on September 10, 2020 Registration No. |
|
| September 8, 2020 |
STB Acceleration Request Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5130 E-mail Address kkennedy@stblaw. |
|
| September 8, 2020 |
Company Acceleration Request September 8, 2020 VIA EDGAR Re: 10x Genomics, Inc. Registration Statement on Form S-1 (File No. 333-248654) Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, 10x Genomics, Inc. (the “Company”) hereb |
|
| September 8, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on September 8, 2020 Registration No. |
|
| September 8, 2020 |
Underwriters' Acceleration Request September 8, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 8, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 10X GENOMICS, INC. [●] Shares of Class A Common Stock, par value $0.00001 per share Underwriting Agreement [●], 2020 J.P. Morgan Securities LLC BofA Securities, Inc. Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc. One Bryant Park |
|
| August 21, 2020 |
Draft Registration Statement Table of Contents CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C. |
|
| August 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 12, 2020 |
ex107 AGREEMENT FOR PURCHASE AND SALE OF PLEASANTON PLAZA, PLEASANTON, CALIFORNIA August 10, 2020 between EQUITY ONE (WEST COAST PORTFOLIO) LLC and 10x GENOMICS, INC. |
|
| August 12, 2020 |
Exhibit 10.6 SECOND AMENDMENT This SECOND AMENDMENT (this “Amendment”) is dated for reference purposes only as of July 24, 2020 (the “Effective Date”) and is entered into by and between 6200 STONERIDGE MALL ROAD INVESTORS LLC, a Delaware limited liability company (“Landlord”) and 10X GENOMICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Leas |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2020 |
10x Genomics Reports Second Quarter 2020 Financial Results Exhibit 99.1 10x Genomics Reports Second Quarter 2020 Financial Results PLEASANTON, Calif. August 11, 2020 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2020. Recent Highlights •Revenue was $42.9 million for the second quarter, representing a 23% decrease over the corresponding period in 2019, with the decline resulting from widespread cu |
|
| June 18, 2020 |
Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2020 |
10x Genomics Reports First Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 10x Genomics Reports First Quarter 2020 Financial Results PLEASANTON, Calif. May 11, 2020 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the quarter ended March 31, 2020. Recent Highlights • Revenue of $71.9 million for the first quarter, representing a 34% increase over the corresponding period of 2019 • Announced a broad range of new products and new |
|
| April 24, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 9, 2020 |
EX-99.1 Exhibit 99.1 10x Genomics Provides COVID-19 Business Impact Update and Response Provides Preliminary Revenue Range for the First Quarter 2020 Withdraws Prior 2020 Annual Revenue Guidance PLEASANTON, Calif. April 9, 2020 – 10x Genomics (Nasdaq: TXG), today provided an update on the actions it is taking to focus its business operations to support critical research in response to the coronavi |
|
| April 9, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 1, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 26, 2020 |
Amended and Restated Bylaws of the Registrant. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF 10X GENOMICS, INC. (Effective March 26, 2020) ARTICLE I Offices SECTION 1.01 Registered Office. The registered office and registered agent of 10x Genomics, Inc. (the “Corporation”) shall be as set forth in the Restated Certificate of Incorporation (as defined below). The Corporation may also have offices in such other places in the United States or |
|
| March 26, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission F |
|
| February 27, 2020 |
TXG / 10x Genomics, Inc. Class A 10-K - Annual Report - 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2020 |
Description of the Registrant’s Securities EX-4.3 Exhibit 4.3 DESCRIPTION OF SECURITIES CAPITAL STOCK As of December 31, 2019, 10x Genomics, Inc. (“10x” or “our”) had one class of securities, our Class A common stock, par value $0.00001 per share (“Class A Common Stock”), registered under Section 12 of the Securities Exchange Act of 1934, as amended. Shares of the Class A Common Stock are traded on The Nasdaq Stock Market LLC under the tra |
|
| February 18, 2020 |
EX-99.1 Exhibit 99.1 10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance Full year 2019 revenue growth of 68% over prior year PLEASANTON, Calif. February 18, 2020 – 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent Highlights • Revenue of $75.3 mil |
|
| February 18, 2020 |
Joint Filing Agreement Pursuant to Rule 13d-1 EX-99.1 EXHIBIT 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rule |
|
| February 18, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| February 18, 2020 |
88025U109 / 10X Genomics Inc / Paladin Capital Management, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 14, 2020 |
88025U109 / 10X Genomics Inc / Sb Investment Advisers (uk) Ltd - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value (Titles of Class of Securities) 88025U109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2020 |
88025U109 / 10X Genomics Inc / Venrock Associates VI, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2020 |
Joint Filing Agreement dated as of February 14, 2020, by and among each of the Reporting Persons EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Class A common stock of 10x Genomics, Inc. may be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. This Agreement ma |
|
| February 14, 2020 |
88025U109 / 10X Genomics Inc / Foresite Capital Fund I, L.p. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* 10x Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Fili |
|
| February 14, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| February 14, 2020 |
88025U109 / 10X Genomics Inc / Meritech Capital Partners V L.p. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. ) * 10X Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 88025U109 (CUSIP Number) December 31, 2019 (Date of Event Which |
|
| December 19, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| December 12, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| December 11, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| December 11, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| November 25, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissio |
|
| November 12, 2019 |
2019 Employee Stock Purchase Plan and forms of agreements thereunder. EX-10.4 Exhibit 10.4 10x GENOMICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Class A Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a Code Section 423 Component (“423 Component”) and a non-Code Section 423 Com |
|
| November 12, 2019 |
TXG / 10x Genomics, Inc. Class A 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2019 |
EX-99.1 Exhibit 99.1 10x Genomics Reports Third Quarter 2019 Financial Results and Provides 2019 Revenue Guidance Q3 2019 revenue growth of 67% over prior year period PLEASANTON, Calif. November 7, 2019 – 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the third quarter ended September 30, 2019. Recent Highlights • Revenue of $61.2 million for the third quarter of 2019, repr |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission |
|
| October 21, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission |
|
| October 18, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commission |
|
| October 10, 2019 |
TXG / 10x Genomics, Inc. Class A / Hindson Benjamin J. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) Benjamin J. Hindson Chief Scientific Officer and President 10x Genomics, Inc. 6230 Stoneridge Mall Drive P |
|
| October 10, 2019 |
TXG / 10x Genomics, Inc. Class A / Saxonov Serge - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* 10x Genomics, Inc. (Name of Issuer) Class A Common Stock, par value $.00001 per share (Title of Class of Securities) 88025U109 (CUSIP Number) Serge Saxonov Chief Executive Officer 10x Genomics, Inc. 6230 Stoneridge Mall Drive Pleasanton, CA 94588 ( |
|
| September 27, 2019 |
Update and Supplement dated September 26, 2019 To the Prospectus dated September 11, 2019 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-233361 Update and Supplement dated September 26, 2019 To the Prospectus dated September 11, 2019 This prospectus supplement (this “Supplement”) relates to the initial public offering of Class A common stock of 10x Genomics, Inc. (“10x Genomics”) and updates and supplements the prospectus dated September 11, 2019 (as supplemented, the “Pro |
|
| September 27, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissi |
|
| September 16, 2019 |
Amended and Restated Bylaws of the Registrant. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF 10X GENOMICS, INC. (Effective September 16, 2019) ARTICLE I Offices SECTION 1.01 Registered Office. The registered office and registered agent of 10x Genomics, Inc. (the “Corporation”) shall be as set forth in the Restated Certificate of Incorporation (as defined below). The Corporation may also have offices in such other places in the United State |
|
| September 16, 2019 |
Amended and Restated Certificate of Incorporation of the Registrant. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 10X GENOMICS, INC. The undersigned, Serge Saxonov, hereby certifies that: ONE: The present name of the corporation is 10x Genomics, Inc. (the “Corporation”). The Corporation was incorporated under the name “Avante Biosystems, Inc.” by the filing of its original certificate of incorporation (as amended and/or restated prior to |
|
| September 16, 2019 |
EX-99.1 Exhibit 99.1 10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares PLEASANTON, Calif. September 16, 2019 – 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to |
|
| September 16, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2019 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39035 45-5614458 (State or other jurisdiction of incorporation) (Commissi |
|
| September 12, 2019 |
Update and Supplement to Preliminary Prospectus Dated September 11, 2019 FWP Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 11, 2019 Relating to Preliminary Prospectus dated September 10, 2019 Registration No. |
|
| September 12, 2019 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-233361 Registration No. 333-233719 Prospectus 10,000,000 shares Class A common stock This is an initial public offering of shares of Class A common stock by 10x Genomics, Inc. We are offering 10,000,000 shares of our Class A common stock to be sold in the offering. The initial public offering price is $39.00 per share. W |
|
| September 12, 2019 |
TXG / 10x Genomics, Inc. Class A S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on September 12, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5614458 (State or other jurisdiction of incorporation or organization) (I.R |
|
| September 11, 2019 |
As filed with the Securities and Exchange Commission on September 11, 2019 Registration No. |
|
| September 11, 2019 |
TXG / 10x Genomics, Inc. Class A CORRESP - - CORRESP VIA EDGAR September 11, 2019 Re: Acceleration Request for 10x Genomics, Inc. |
|
| September 10, 2019 |
Table of Contents As filed with the Securities and Exchange Commission on September 10, 2019. |
|
| September 10, 2019 |
Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5130 E-mail Address kkennedy@stblaw. |
|
| September 10, 2019 |
Exhibit 10.3 SECOND AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into this 9th day of September 2019, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and 10X GENOMICS, INC., a Delaware corporation (?Borrower?). RECITALS A. Bank and Borrower ha |
|
| September 10, 2019 |
TXG / 10x Genomics, Inc. Class A CORRESP - - CORRESP VIA EDGAR September 10, 2019 Re: Acceleration Request for 10x Genomics, Inc. |
|
| September 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5614458 (State of incorporation or organization) (I.R.S. Employer Identification No.) 6230 Stoneridge Mall Road |
|
| September 3, 2019 |
Amended and Restated 2012 Stock Plan and forms of award agreements thereunder. Exhibit 10.10 10x GENOMICS, INC. AMENDED AND RESTATED 2012 STOCK PLAN 1. Purposes of the Plan. The purposes of this 10x Genomics, Inc., Amended and Restated 2012 Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants, and to promote the success of the Company?s business. Options gra |
|
| September 3, 2019 |
Exhibit 10.17 10X GENOMICS, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement is dated as of , 20 (this ?Agreement?) and is between 10x Genomics, Inc., a Delaware corporation (the ?Company?), and [name of director/officer] (?Indemnitee?). Background The Company believes that in order to attract and retain highly competent persons to serve as directors or in other capacities, in |
|
| September 3, 2019 |
Table of Contents As filed with the Securities and Exchange Commission on September 3, 2019. |
|
| September 3, 2019 |
Exhibit 10.12 10x GENOMICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Class A Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a Code Section 423 Component (?423 Component?) and a non-Code Section 423 Component |
|
| September 3, 2019 |
2019 Omnibus Incentive Plan and forms of award agreements thereunder. Exhibit 10.11 10x GENOMICS, INC. 2019 OMNIBUS INCENTIVE PLAN 1. Purpose. The purpose of the 10x Genomics, Inc. 2019 Omnibus Incentive Plan is to provide a means through which the Company and the other members of the Company Group may attract and retain key personnel, and to provide a means whereby directors, officers, employees, consultants, and advisors of the Company and the other members of the |
|
| September 3, 2019 |
Form of Underwriting Agreement. Exhibit 1.1 10X GENOMICS, INC. [?] Shares of Class A Common Stock, par value $0.00001 per share Underwriting Agreement [?], 2019 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC 200 West Street New |
|
| September 3, 2019 |
Exhibit 3.4 FORM OF AMENDED AND RESTATED BYLAWS OF 10X GENOMICS, INC. (Effective [?], 2019) ARTICLE I Offices SECTION 1.01 Registered Office. The registered office and registered agent of 10x Genomics, Inc. (the ?Corporation?) shall be as set forth in the Restated Certificate of Incorporation (as defined below). The Corporation may also have offices in such other places in the United States or els |
|
| September 3, 2019 |
Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5130 E-mail Address kkennedy@stblaw. |
|
| August 19, 2019 |
Exhibit 10.5 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT This License Agreement (this ?Agreement?) is entered into as of this 26th day of September, 2013 (the ?Effective Date?), by and between 10X Technologies, Inc., a Delaware Corporation having a place of business at 7068 K |
|
| August 19, 2019 |
Table of Contents As filed with the Securities and Exchange Commission on August 19, 2019. |
|
| August 19, 2019 |
Form of Stock Certificate for Class A common stock of the Registrant. Exhibit 4.2 Exhibit 4.2 FORM OF STOCK CERTIFICATE Number 10X GENOMICS, INC. ** Shares A DELAWARE CORPORATION Class A Common Stock CUSIP 88025U 109 THIS CERTIFIES THAT ** is the record holder of * ()* fully paid and non-assessable shares of Class A Common Stock, par value $0.00001 per share, of 10x Genomics, Inc., a Delaware corporation, transferable on the books of the corporation in person or by |
|
| August 19, 2019 |
Exhibit 10.3 LEASE AGREEMENT BY AND BETWEEN 6200 STONERIDGE MALL ROAD INVESTORS LLC, a Delaware limited liability company AS LANDLORD and 10X GENOMICS, INC., a Delaware corporation AS TENANT DATED August 2, 2018 TABLE OF CONTENTS Page Index of Defined Terms iv Basic Lease Information v 1.??Demise 1 2.??Premises 1 3.??Term 2 4.??Rent 2 5.??Utilities and Services 13 6.??Late Charge 16 7.??Letter of |
|
| August 19, 2019 |
Exhibit 10.6 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. Amendment No. 1 to License Agreement This Amendment No. 1 to License Agreement (this ?Amendment No. 1?) is entered into as of this 25th day of October, 2018 ( the ?Amendment No. 1 Execution Date?), and shall be deemed effective as of Apr |
|
| August 19, 2019 |
Exhibit 10.16 10X Genomics, Inc. AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, AND ARBITRATION AGREEMENT As a condition of my employment with 10X Genomics, Inc., its subsidiaries, affiliates, successors or assigns (together, the ?Company?), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, I agre |
|
| August 19, 2019 |
Employment Offer Letter by and between the Registrant and Justin McAnear. Exhibit 10.15 Justin McAnear Dear Justin: I am very pleased to offer you a position with 10x Genomics, Inc. (the ?Company?), as Chief Financial Officer based in Pleasanton, California. The following will outline the terms of your employment: Position: Your start date will be September 28, 2018, or such other date as may be mutually agreed upon between you and the Company (the ?Start Date?). Your t |
|
| August 19, 2019 |
Exhibit 10.2 FIRST AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into this 26th day of June, 2019, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and 10X GENOMICS, INC., a Delaware corporation (?Borrower?). RECITALS A. Bank and Borrower have en |
|
| August 19, 2019 |
Exhibit 4.1 10X GENOMICS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT This Amended and Restated Investors? Rights Agreement (this ?Agreement?) is made and entered into as of October 18, 2018 by and among 10X Genomics, Inc., a Delaware corporation (the ?Company?), Serge Saxonov, Benjamin Hindson and Kevin Ness (the ?Founders?), the holders of Series A-1 Preferred Stock (the ?Series A-1 Pr |
|
| August 19, 2019 |
Exhibit 10.9 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT No 2 TO THE LICENSE AGREEMENT EFFECTIVE THE 15th Day of October 2015 BETWEEN STANFORD UNIVERSITY AND EPINOMICS Effective the 27th day of July 2018, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (?Stanford?), an |
|
| August 19, 2019 |
Employment Offer Letter by and between the Registrant and Eric S. Whitaker. Exhibit 10.14 Eric S. Whitaker Piedmont, CA Dear Eric, I am pleased to offer you a position with 10x Genomics, Inc. (the ?Company?), as General Counsel based in Pleasanton, California. If you decide to join us, you will receive a monthly salary of $25,000.00, which will be paid semi-monthly in accordance with the Company?s normal payroll procedures. As a full-time employee, you will also be eligib |
|
| August 19, 2019 |
TXG / 10x Genomics, Inc. Class A CORRESP - - CORRESP Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5130 E-mail Address kkennedy@stblaw. |
